Scarica l'app Stockscreener
0.0201
30.45%
-0.0088
Dopo l'orario di chiusura:
.02
-0.000100
-0.50%
Precedente Chiudi:
$0.0289
Aprire:
$0.0234
Volume 24 ore:
254.59M
Relative Volume:
8.51
Capitalizzazione di mercato:
$2.21M
Reddito:
$1.44M
Utile/perdita netta:
$-3.21M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-79.70%
1M Prestazione:
-81.39%
6M Prestazione:
-97.13%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.019
$0.0244
Intervallo di 1 settimana:
$0.019
$0.105
Portata 52W:
$0.019
$4.2442
Elevai Labs Inc Stock (ELAB) Company Profile
Nome
Elevai Labs Inc
Settore
Industria
Telefono
18667944940
Indirizzo
120 NEWPORT CENTER DRIVE, NEWPORT BEACH
Elevai Labs Inc Borsa (ELAB) Ultime notizie
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewswire
Elevai Labs strikes new executive agreements - Investing.com India
Elevai Labs strikes new executive agreements By Investing.com - Investing.com UK
Elevai Biosciences gears up for obesity drug IND submission By Investing.com - Investing.com Nigeria
Elevai Biosciences gears up for obesity drug IND submission - Investing.com
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., - GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity - Yahoo Finance UK
Elevai reports promising preclinical obesity treatment results By Investing.com - Investing.com South Africa
Elevai reports promising preclinical obesity treatment results - Investing.com
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity - The Manila Times
ELAB stock’s current quarter earnings estimates: What analysts predict? - US Post News
Elevai Labs Inc. Inc. (ELAB) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Metric Deep Dive: Understanding Elevai Labs Inc. (ELAB) Through its Ratios - The Dwinnex
Insider’s View: Deciphering Elevai Labs Inc. (ELAB)’s Financial Health Through Ratios - The Dwinnex
Views of Wall Street’s Leading Experts on Elevai Labs Inc. - SETE News
Elevai Labs Inc. [ELAB] is -94.09% lower this YTD. Is it still time to buy? - The DBT News
Elevai Labs Inc. (ELAB) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock - ForexTV.com
Elevai Labs Inc. Commences Offer to Exchange Up to - GlobeNewswire
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - ForexTV.com
Elevai files patents for obesity treatment EL-22 By Investing.com - Investing.com Australia
Elevai files patents for obesity treatment EL-22 - Investing.com
This tiny skincare company is up big 💪 - RagingBull
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - StockTitan
Elevai Labs commences exosome skincare study By Investing.com - Investing.com South Africa
Elevai Labs commences exosome skincare study - Investing.com India
ELABElevai Labs, Inc. Latest Stock News & Market Updates - StockTitan
Elevai Labs begins clinical study of topical exosome product - TipRanks
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., - GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining - The Bakersfield Californian
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device - StockTitan
Check out these key findings about Elevai Labs Inc. (ELAB) - SETE News
ELAB Stock Update: Elevai Labs Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
What is ELAB’s price-to-sales ratio telling us about the company’s value? - US Post News
Elevai Labs Inc. [ELAB] Revenue clocked in at $2.47 million, down -94.95% YTD: What’s Next? - The DBT News
In the Green: Elevai Labs Inc. (ELAB) Closes at 0.09, Up/Down 3.71 from Previous Day - The Dwinnex
Elevai Labs Inc.’s Banking’s 100-Day Moving Average at 0.4636: Will the Stock Break Through? - The InvestChronicle
Biotech Alert: Searches spiking for these stocks today - TipRanks
Altium Capital Management LP Acquires New Stake in Elevai Labs Inc - Yahoo Finance
Elevai Labs stock offering raises $8 million - Sacramento Business Journal
Univest Securities, LLC Announces Closing of $8.0 Million - GlobeNewswire
Elevai Labs announces pricing of $8 million public offering - MSN
Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB) - ForexTV.com
Evolus Inc (EOLS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Evolv Technologies (NASDAQ:EVLV) Shares Down 2.9% - Defense World
EverSource Wealth Advisors LLC Raises Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down to $23.57 - MarketBeat
Logos Global Management LP Lowers Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
First Light Asset Management LLC Has $27.63 Million Stake in Evolent Health, Inc. (NYSE:EVH) - Defense World
Evolv Technologies Holdings Inc (EVLV) looking to reclaim success with recent performance - SETE News
Stock Market Recap: Evolus Inc (EOLS) Concludes at 15.53, a -6.16 Surge/Decline - The Dwinnex
Elevai Labs Inc Azioni (ELAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.11%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):